Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Preprint |
| Published: |
2026
|
| Subjects: | |
| Online Access: | https://arxiv.org/abs/2603.23775 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- A major barrier to decentralized, near-patient diagnostics is the lack of a signal transduction modality that is both analytically precise and accessible at the point of care. Optical readouts remain instrument-dependent and difficult to miniaturize, while compact electrochemical readouts are prone to matrix-derived signal distortion, limiting their biomarker coverage in real clinical settings. Here, we define interfacial potential transduction as a standardized electrical modality for portable, clinical-grade diagnostics across diverse assay formats. A mechanistic framework identifying key sample matrix parameters within the interfacial potentials transduction system enables control of biofluid-derived interference, and is demonstrated in a widely accessible lateral flow immunoassay format through quantitative detection of estradiol, progesterone, and luteinizing hormone in human plasma with high correlation (r2 > 0.97) to clinical analyzers. Broader applicability across representative diagnostic sectors is further demonstrated through exceptional performance including glucose quantification for biochemical analysis with limit of detection (LOD) of 0.92 ug/dL, HIV p24 capsid protein under an immunomagnetic separation workflow (LOD = 44.8 fg/mL), and hepatitis B virus detection within 5 min via loop-mediated isothermal amplification for molecular diagnostics. Together, these results establish interfacial potentials transduction as a unified diagnostic paradigm for near-patient deployment beyond optical and electrochemical approaches.